BACIL PHARMA LIMITED

Reg Office: G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400099
Email Id: bacilpha@yahoo.com, CIN: L24200MH1987PLC043427, Tel: 22618452/22661541, Tel/Fax: 22618327

Date: 13.02.2026

To,
Gen. Manager (DCS)
BSE Limited.
P J Towers, Dalal Street,
Fort, Mumbai-400001

Scrip Code: 524516
Scrip Id: BACPHAR

Sub: Outcome of the Board Meeting held on Friday, 13th February, 2026

Ref: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we wish to inform you that the Meeting of the Board of Directors of Bacil Pharma Limited was held on Friday, 13th February, 2026 at the Registered Office of the Company, wherein the Board has, inter alia,considered and approved the following:

1. Approved the Unaudited Financial Results of the Company for the quarter and Nine Month ended December 31, 2025, along with the Limited Review Report issued by the Statutory Auditors of the Company.

The meeting of the Board of Directors commenced at 01:00P.M. and concluded at 02:00 P.M.

The Unaudited Financial Results and Limited Review Report will be submitted separately in the prescribed format as per SEBI LODR Regulations.

Kindly take the above on your record and acknowledge the receipt.

Thanking you,.
Sincerely,
For Bacil Pharma Limited

Shah Chaitali Kalpataru
Digitally signed by Shah Chaitali Kalpataru
Date: 2026.02.13 19:52:30 +05'30'

Ms. Chaitali Kalpataru Shah
Director & CFO
DIN: 11167778

BACIL PHARMA LIMITED

{CIN : L24200MH1987PLC043427}

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER,2025

(₹ in Lakhs)

Sr. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	-	-	-		-	-
	Other income	6.45	5.49	0.30	112.19	57.40	66.14
	Total revenue	6.45	5.49	0.30	112.19	57.40	66.14
2	Expenses						
	Employee benefits expense	0.60	0.63	3.90	4.18	10.21	13.84
	Depreciation and amortization expense	-	-	-	-	0.04	0.07
	Other expenses	1.93	3.02	2.60	12.89	8.00	11.47
	Total expenses	2.53	3.65	6.50	17.07	18.25	25.38
	Profit / (Loss) from ordinary activities before tax	3.92	1.84	(6.20)	95.12	39.15	40.76
3	Tax expense:						
	Current tax	-	(0.46)	-	(22.95)	-	-
	Deferred tax	-	-	-	-	(0.34)	(0.34)
4	Profit/(Loss) from ordinary activities after tax	3.92	1.38	(6.20)	72.17	38.81	40.42
5	Other Comprehensive Income (OCI)						
	Item that will not be reclassified to profit or loss						
	Gain/(Loss) on recognised on fair valuation of Financial Assets	2.18	(1.86)	-	8.87	(29.78)	(0.49)
	Income tax relating to these items	0	1.40	-	(0.82)	7.74	0.13
	Total Other Comprehensive Income (OCI)	2.18	(0.46)	-	8.05	(22.04)	(0.36)
	Profit/(Loss) for the Period	6.10	0.92	(6.20)	80.22	16.77	40.06
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	1,397.03	1,397.03	589.00	1,397.03	589.00	1,397.02
6	Earning Per Share (EPS) (Not annualised)						
	(1) Basic	0.03	0.01	(1.00)	0.52	0.66	0.64
	(2) Diluted	0.03	0.01	(1.00)	0.52	0.66	0.64

Notes:

1. The Above Financial Results were reviewed by the audit committee of the board on 13-02-2026 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditor have expressed on unmodified opinion. The review report has been filled with stock exchange and is available on the company's website. The Financial results have been prepared in accoradance with Ind As notified under the companies (Accounting Standards) Rule 2015.

2. Figures for the corresponding quarter ended i.e. 31st March 2025 in the previous year as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year.

3. The Company has single business segment therefore in the context of Ind As 108, disclosure of segement information is not applicable.

4. Previous quarter figures have been regrouped /reclassified whereever necessary, to make them comparable.

For and on behalf of the Board

Bacil Pharma Limited

Shah Chaitali Kalpataru

Digitally signed by Shah Chaitali Kalpataru
Date: 2026.02.13 19:53:04 +05'30'

CHAITALI KALPATARU SHAH

(Director & CFO)

DIN: 11167778

Date: 13-02-2026

SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

Independent Auditor's Review Report on the Quarter Ended 31st December,2025 Unaudited Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors
BACIL PHARMA LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of BACIL PHARMA LIMITED (the "Company") for the Quarter ended December,2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "listing Regulations").

2. This Statement, which is the responsibility of Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ("Ind AS 34), "Interim Financial Reporting", prescribed under Section 133 of Companies Act, 2013 and other accounting principles generally accepted in india. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of the Interim financial information consists of making inquires , Primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not have any Modified opinion.

SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES
FRN NO.: 159649W
AHMEDABAD
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

4. The information and data contained in this report are based solely on the documents, explanations, and representations provided by the management of the entity. We have not independently verified the correctness or completeness of such information and records, and our verification has been limited to the extent of information made available to us during the course of our review.

5. Emphasis of Matter

(i) The Company has not raised any funds during the year through the allotment of Shares.

(ii) This report is prepared for the exclusive use of the entity and is based on a limited review; it should not be considered as an audit or certification of factual accuracy. We do not assume responsibility to update or revise the report for events occurring after the date of issuance. Nothing contained herein should be construed as an assurance of future performance, compliance, or financial position of the entity. Our responsibility is restricted to the reporting requirements as per the scope of engagement agreed with management and in accordance with the Standards on Quality Control (SQC 1) and relevant Guidance Notes issued by ICAI.This report does not, in any manner, express an audit opinion under the Companies Act, 2013 or under any other statute. The management is responsible for compliance with applicable laws and maintenance of adequate internal controls.

(iii) During the course of our review, it was observed that the Company has complied with statutory requirements under the Goods and Services Tax Act, 2017 and the Income-tax Act, 1961 relating to timely deposit and filing of GST returns except delay in filing in tds return. In our opinion, Company comply with all statutory provisions except tds return which may not have any material impact on the financial statements. The above observation is based solely on information and explanations provided by management and our limited review procedures.

SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES
FRN NO.: 159649W
AHMEDABAD
CHARTERED ACCOUNTANTS

SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES

CHARTERED ACCOUNTANTS

INDIA

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

(iv) Based on our review conducted as above , nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable principles laid down in Indian Accounting Standards 34 " Interim Financial Reporting"("Ind AS 34") prescribed under section 133 of companies Act,2013 read with relevant rules issued there under and other accounting principles generally accepted in india and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, Including the Manner in which it is to be disclosed or that it contains any material misstatement.

(v) Our Opinion is not modified in respect of above matters.

FOR
SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES
CHARTERED ACCOUNTANTS
FRN: 159649W

CA SARANG CHAVAN
(PROPRIETOR)
M.NO.142576
UDIN: 26142576DQIWIP7118
Date: 13/02/2026
Place: Ahmedabad

SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES
FRN NO.: 159649W
AHMEDABAD
CHARTERED ACCOUNTANTS